Introduction
components and synaptic vesicles, whereas statins block dendrite outgrowth and axonal branching [4] . The role of cholesterol in AD pathogenesis is still controversial [5] . High cholesterol levels as risk factor for AD were first proposed in the early 1990s and since then considerable biochemical and clinical research has claimed the existence of a link between cholesterol, statin therapy and AD development [6] [7] [8] [9] [10] . On the other hand, it is known that hydrophilic statins do not cross the blood brain barrier and that brain cholesterol progressively reduces with increasing age (the main risk factor for sporadic AD), such decrease appearing considerably accelerated in AD people [11] . Presently, the question of whether statins can lower the incident rate of AD remains unresolved [12] . Recent findings suggest that the proteolytic machinery required for A␤ generation is located within lipid rafts or detergent-resistant membranes (DRMs) that are discrete cholesterol-rich microdomains of the cell membrane involved in a wide range of key biological processes [13, 14] .
A key role of membrane cholesterol as a modulator of A␤ peptide production and clearance [15] as well as aggregation and neurotoxicity [16] [17] [18] [19] [20] [21] [22] . Accordingly, rodents treated with lovastatin, the most permeable statin to the blood brain barrier, display increased A␤ production and senile plaque deposition [23] . Altogether, these data support a link between AD pathogenesis and loss of brain cholesterol suggesting that a fine modulation of the levels of this membrane sterol plays a crucial role in neuronal viability. [24] . Seladin-1 overexpression appears to protect neuroglioma H4 cells against A␤-mediated toxicity by reducing oxidative stress and caspase 3 activity [24] . Remarkably, the gene product is identical to DHCR24, the enzyme that catalyses the last step of cholesterol biosynthesis by reducing the ⌬24 double bond of desmosterol. A mutation of this gene is associated with desmosterolosis, a severe disease which affects, among others, the nervous system [25] . We [26] . This finding provides a new experimental approach to study the role of membrane cholesterol in the early events associated with neurodegeneration. Our recent studies demonstrate an hormonal regulation of seladin-1 expression [27, 28] 
has recently been described. In the hippocampus of healthy humans and transgenic mice expressing moderate levels of human APP only a small pool of endogenous APP and ␤ site APP cleaving Enzyme or ␤-secretase (BACE) colocalize in the same membrane environment. An increased APP/BACE colocalization, likely caused by lipid raft disorganization, is found in hippocampal membranes from AD patients or in rodent hippocampal neurons with a moderate reduction of membrane cholesterol and is associated with elevated A␤ production. DRMs disruption also results in reduced activity of the A␤-degrading enzyme plasmin because of decreased plasminogen binding to the plasma membrane

Seladin-1, a recently characterized gene, is down-regulated in neurons of AD-affected brain areas
have recently shown that seladin-1 expression in human mesenchymal stem cells (hMSC) is abundant, but decreases dramatically upon differentiation into a neuronal phenotype (hMSC-n) with concomitant reduction of the total content of cholesterol
Materials and methods
Materials and cell culture
Cholesterol and desmosterol measurements
The amount of cholesterol in the cells was determined by gas chromatography-mass spectrometry (GC-MS) as previously described with minor modifications [26] . (Fig. 3A) . Conversely, the same amyloid oligomers added to the cell culture medium appear to accumulate more quickly and to a greater extent at the plasma membrane in ⌬22 and ␤-CD treated cells characterized by a reduced content of cholesterol than in control cells (Fig. 3A) . [29] that is involved in A␤ degradation [20] . 
Amyloid cytotoxicity assay
Fig. 2 ⌬22 inhibits seladin-1 enzymatic activity. (A) Desmosterol accumulation during the treatment of SH-SY5Y cells with 10 µM ⌬22 measured in total cell lysates. (B) MTT assay on SH-SY5Y treated for 24 and
48 hrs with 10 µM ⌬22. [32, 39, 40] [29] . [24] are responsible for either the reduction of membrane cholesterol described in those brains [21] [41, 42] and to control the [44] . It was hypothesized that A␤ adopts an altered conformation through its binding to GM1 acting as a seed for A␤ fibrillogenesis in AD brain [44] . It has also been reported that GM1 clusters are susceptible to membrane cholesterol depletion [45] . Recent evidence suggests that A␤ interacts with the APP present at the cell surface and acts as a ligand of its own precursor, resulting in a cell death-related signal [46] [39, 52] or from the formation of membrane pores [30, [49] [50] [51] and either oxidative stress [53] and cell death [54] . Overall, our results provide information useful to depict a mechanism of cell impairment and death that can be common to pre-fibrillar aggregates of most peptides and proteins. It apparently starts with aggregate binding to the cell membrane resulting in membrane permeabilization, subsequent alteration of ion distribution inside exposed cells and oxidative stress [32, 55] [12] . In particular, they suggest that a mild loss of neuronal membrane cholesterol results not only in altered APP processing with increased A␤ production [15, 29] 
Fig. 3 Increasing cell cholesterol reduces amyloid-␤ peptide (A␤) aggregate interaction with the cell membrane. (A, B) Representative confocal microscopy images showing aggregates in contact with, and penetrating into, the plasma membrane of neuroblastoma cells under different experimental conditions. Cells transfected with empty expression plasmid without seladin-1 gene (C Sel) and cells exposed to ethanol (C
Seladin-1 protects against alteration of intracellular Ca 2+ levels in cells exposed to A␤ aggregates
Derangement of ion distribution across the plasma membrane is a shared and early biochemical modification displayed by cells exposed to toxic amyloid aggregates
Conversely, inhibiting the enzymatic activity of seladin-1 resulted in a significant reduction of total and membrane cell cholesterol. As far as we know, this is the first time that a reduction of the enzymatic activity of seladin-1 is correlated to a decrease of membrane cholesterol and an increase of cell vulnerability to aggregate toxicity. In spite of the limitation of the cell model used, this finding supports the idea that the low seladin-1 levels found in AD brains
